| European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors |
72 |
| European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas |
72 |
| Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society |
51 |
| Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016 |
37 |
| Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery |
36 |
| Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis |
26 |
| Differences between ATA, AACE/ACE/AME and ACR TI-RADS ultrasound classifications performance in identifying cytological high-risk thyroid nodules |
26 |
| Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing |
26 |
| Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study |
23 |
| The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma |
20 |
| DIAGNOSIS OF ENDOCRINE DISEASE Congenital hypothyroidism: update and perspectives |
20 |
| GENETICS IN ENDOCRINOLOGY Approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 'DSDnet' |
19 |
| MANAGEMENT OF ENDOCRINE DISEASE Novel anabolic treatments for osteoporosis |
18 |
| MECHANISMS IN ENDOCRINOLOGY Hypophysitis: diagnosis and treatment |
18 |
| Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency |
18 |
| Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review |
18 |
| Are all GLP-1 agonists equal in the treatment of type 2 diabetes? |
17 |
| Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT) |
17 |
| Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY |
17 |
| Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study |
17 |
| SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? |
16 |
| Radiofrequency ablation for benign thyroid nodules according to different ultrasound features: an Italian multicentre prospective study |
16 |
| ANNIVERSARY REVIEW Antithyroid drug therapy: 70 years later |
16 |
| Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas |
15 |
| Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis |
15 |
| Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures |
15 |
| Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study |
14 |
| MECHANISMS IN ENDOCRINOLOGY Estradiol as a male hormone |
14 |
| Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH) |
14 |
| Management of Cushing's syndrome during pregnancy: solved and unsolved questions |
14 |
| Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study |
14 |
| Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis |
14 |
| Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre |
14 |
| New genetic findings in a large cohort of congenital hypogonadotropic hypogonadism |
14 |
| Aggressive pituitary tumours and carcinomas: two sides of the same coin? |
13 |
| Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas |
13 |
| Bone turnover markers: are they clinically useful? |
13 |
| TIRADS score is of limited clinical value for risk stratification of indeterminate cytological results |
13 |
| Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects? |
12 |
| Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited |
12 |
| Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case control study |
12 |
| Somatic and germline mutations in the pathogenesis of pituitary adenomas |
12 |
| A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma |
12 |
| The impact of environmental temperature on the diagnosis of gestational diabetes mellitus |
12 |
| The genetic characteristics of congenital hypothyroidism in China by comprehensive screening of 21 candidate genes |
11 |
| Personalized medicine in the treatment of acromegaly |
11 |
| Early diagnosis of gestational diabetes mellitus using circulating microRNAs |
11 |
| Time to parathyroid function recovery in patients with protracted hypoparathyroidism after total thyroidectomy |
11 |
| Immune check point inhibitors-induced hypophysitis |
11 |
| Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas |
11 |
